Good
Mostly Aligned
Patient Risk:
Moderate
Summary
Most clinical/label-relevant claims (PTHrP analog, bone formation, BMD, fracture risk, indication, daily SC dosing, osteosarcoma wording/unknown in humans, hypercalcemia, contraindication to pre-existing hypercalcemia, and prescription status) align with the provided label excerpts. However, some safety-administration details are either overstated or not fully supported by the supplied label text (notably the 2-year general-use limit and contraindication phrasing about 'certain pre-existing conditions'), and the patient assistance/savings program claims are not part of the FDA prescribing information.
Category Scores
Accurate Statements
Tymlos (abaloparatide) is a parathyroid hormone-related peptide (PTHrP) analog.
Section 12.1: “Abaloparatide is a PTHrP(1-34) analog …”
Tymlos stimulates bone formation.
Section 12.1: “stimulates new bone formation”
Tymlos increases bone mineral density.
Section 14.1: “significant increases in BMD …”
Tymlos reduces the risk of fractures.
Section 1: “TYMLOS reduces the risk of vertebral fractures and nonvertebral fractures.” Also supported by Section 14.1 efficacy endpoints.
Tymlos is administered as a daily subcutaneous injection.
Section 2: “80 mcg administered subcutaneously once daily.”
Tymlos is used to treat osteoporosis in postmenopausal women at high risk for fracture.
Section 1: indicated for “postmenopausal women with osteoporosis at high risk for fracture …”
Tymlos carries a boxed warning regarding the risk of osteosarcoma.
Section 5.1 is titled “Risk of Osteosarcoma.” (The provided excerpts do not explicitly show the boxed-warning formatting, but the label section text provided supports the osteosarcoma warning content.)
The risk of osteosarcoma with Tymlos has been observed in rats.
Section 5.1: “Abaloparatide caused a dose-dependent increase in the incidence of osteosarcoma in male and female rats…”
It is unknown if Tymlos increases the risk of osteosarcoma in humans.
Section 5.1: “It is unknown whether TYMLOS will cause osteosarcoma in humans.”
Tymlos may cause hypercalcemia.
Section 5.3: “TYMLOS may cause hypercalcemia…”
Tymlos is a prescription medication.
Not directly supported by the provided label excerpts.
Unsupported Statements
Due to the osteosarcoma risk, Tymlos should generally not be used for longer than 2 years.
The provided label excerpts include osteosarcoma risk and general precautions (avoid use in patients at increased baseline risk) but do not include any “generally not longer than 2 years” statement.
Tymlos should not be used by patients with certain pre-existing conditions.
The excerpts provided support specific conditions (e.g., not recommended in patients with pre-existing hypercalcemia; and avoidance in patients at increased baseline risk of osteosarcoma), but the claim is generic and not directly stated as such in the provided text.
Astellas Pharma US offers patient assistance programs for Tymlos that may provide eligible patients with free or low-cost medication.
Patient assistance/savings program information is not present in the provided FDA prescribing information excerpts and cannot be verified against label content.
Tymlos has a savings program that can help eligible commercially insured patients save on their out-of-pocket costs.
Savings program language is not present in the provided FDA prescribing information excerpts and cannot be verified against label content.
Tymlos carries a boxed warning regarding the risk of osteosarcoma.
The excerpts show osteosarcoma risk in Section 5.1 but do not explicitly confirm boxed-warning formatting in the provided label text.
Tymlos is a prescription medication.
Prescription-status language is not contained in the provided label excerpts.
Contradictions
Important Omissions
Administration instruction specifics beyond daily SC (e.g., periumbilical region of abdomen, rotate site, do not administer IV/IM).
Importance:
Low
Safety Assessment
Potential Patient Risk:
Moderate
The main potentially unsafe inaccuracy/overreach is the unsupported “generally not longer than 2 years” duration claim. Generic contraindication language is also less precise than supported excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Mostly Aligned
Primary Issue
Unsupported dosing-duration and generic contraindication phrasing; non-label patient assistance/savings program claims.
Suggested Improvement
Remove or qualify the “not longer than 2 years” statement unless it is present in the provided label text; make contraindication/avoidance statements specific to the conditions explicitly stated in the excerpts (e.g., pre-existing hypercalcemia; baseline osteosarcoma risk conditions). Exclude patient assistance/savings program claims unless they are explicitly included in the FDA label content provided.